Phase IV, Multicenter, Open-label Study to Evaluate the Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Disorders in Subjects Aged 2 to 16
Clinical Trial Grant
Administered By
Pediatrics, Allergy and Immunology
Awarded By
ADMA Biologics
Start Date
October 26, 2020
End Date
December 30, 2022
Administered By
Pediatrics, Allergy and Immunology
Awarded By
ADMA Biologics
Start Date
October 26, 2020
End Date
December 30, 2022